Laekna, Inc. (HK:2105) has released an update.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Laekna, Inc. has entered into a clinical collaboration with Eli Lilly to develop LAE102, a promising drug candidate aimed at treating obesity. This partnership will see Lilly funding and executing a phase I study in the U.S., while Laekna retains global rights to the monoclonal antibody that targets muscle regeneration and lipid metabolism. This development could position LAE102 as a novel option for quality weight control, attracting investor interest in Laekna’s future endeavors.
For further insights into HK:2105 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- ‘This Is Just Pure Hype,’ Says Top Investor About Tesla Stock
- Will Palantir Stock Crash to $28? Jefferies Sounds the Alarm
- ‘Don’t Dive in Just Yet,’ Says RBC About Lucid Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
